$IRD
Opus Genetics, Inc. Stock $ird

$ird Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000114036120018406 Filed on August 14, 2020

Income Statement

Concept	2020 Q3	2020 Q2	2019 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.360M	$2.120M	$1.340M
YoY Change	18.26%	58.21%	-14.65%
% of Gross Profit
Research & Development	$149.6K	$231.6K	$1.648M
YoY Change	-86.78%	-85.95%	-51.94%
% of Gross Profit
Depreciation & Amortization	$1.000K	$10.00K	$10.00K
YoY Change	-90.0%	0.0%	-50.0%
% of Gross Profit
Operating Expenses	$1.506M	$2.348M	$2.988M
YoY Change	-33.97%	-21.41%	-40.25%
Operating Profit	-$1.506M	-$2.348M	-$2.988M
YoY Change	-33.97%	-21.41%	-40.25%
Interest Expense	$100.0K	-$160.0K	$520.0K
YoY Change	-68.75%	-130.77%	-55.17%
% of Operating Profit
Other Income/Expense, Net	$102.4K	-$162.7K	$524.1K
YoY Change	-68.14%	-131.03%	-54.94%
Pretax Income	-$1.403M	-$2.511M	-$2.464M
YoY Change	-28.36%	1.9%	-35.8%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.248M	-$2.511M	-$2.464M
YoY Change	-36.3%	1.9%	-35.8%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.321M	-$2.510M	-$2.460M
COMMON SHARES
Basic Shares Outstanding	4.234M	4.019M	4.019M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.080M	$9.210M	$16.26M
YoY Change	-41.91%	-43.36%	-2.87%
Cash & Equivalents	$8.080M	$9.209M	$7.310M
Short-Term Investments	$0.00	$0.00	$8.950M
Other Short-Term Assets	$570.0K	$820.0K	$662.1K
YoY Change	-6.0%	23.85%	-51.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.653M	$10.03M	$17.29M
YoY Change	-40.88%	-42.02%	-4.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$150.0K	$57.31K	$94.69K
YoY Change	75.85%	-39.47%	-5.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$30.00K	$30.00K	$30.00K
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$180.6K	$222.5K	$384.0K
YoY Change	-47.65%	-42.07%	195.4%
TOTAL ASSETS
Total Short-Term Assets	$8.653M	$10.03M	$17.29M
Total Long-Term Assets	$180.6K	$222.5K	$384.0K
Total Assets	$8.834M	$10.25M	$17.68M
YoY Change	-41.03%	-42.02%	-3.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.840M	$1.650M	$950.0K
YoY Change	411.11%	73.68%	31.94%
Accrued Expenses	$510.0K	$680.0K	$1.110M
YoY Change	-55.26%	-38.74%	-58.27%
Deferred Revenue	$650.0K	$650.0K	$1.500M
YoY Change	-56.67%	-56.67%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.009M	$2.977M	$3.551M
YoY Change	0.25%	-16.17%	5.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$110.0K	$270.0K	$500.0K
YoY Change	-50.0%	-46.0%	-85.42%
Total Long-Term Liabilities	$110.0K	$270.0K	$500.0K
YoY Change	-50.0%	-46.0%	-85.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.009M	$2.977M	$3.551M
Total Long-Term Liabilities	$110.0K	$270.0K	$500.0K
Total Liabilities	$3.120M	$3.246M	$4.054M
YoY Change	-3.42%	-19.94%	-40.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$167.8M	-$166.4M	-$159.5M
YoY Change	3.95%	4.34%
Common Stock	$173.5M	$173.4M	$173.1M
YoY Change		0.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.410M	$7.003M	$13.62M
YoY Change
Total Liabilities & Shareholders Equity	$8.834M	$10.25M	$17.68M
YoY Change	-41.03%	-42.02%	-3.09%

Cashflow Statement

Concept	2020 Q3	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$1.248M	-$2.511M	-$2.464M
YoY Change	-36.3%	1.9%	-35.8%
Depreciation, Depletion And Amortization	$1.000K	$10.00K	$10.00K
YoY Change	-90.0%	0.0%	-50.0%
Cash From Operating Activities	-$1.130M	-$1.790M	-$1.810M
YoY Change	-52.32%	-1.1%	-59.33%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$3.000M
YoY Change	-100.0%	-100.0%	-7.69%
Cash From Investing Activities	$0.00	$0.00	$3.000M
YoY Change	-100.0%	-100.0%	-7.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-1.130M	-1.790M	-1.810M
Cash From Investing Activities	0.000	0.000	3.000M
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-1.130M	-1.790M	1.190M
YoY Change	-279.37%	-250.42%	-199.17%
FREE CASH FLOW
Cash From Operating Activities	-$1.130M	-$1.790M	-$1.810M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$1.130M	-$1.790M	-$1.800M
YoY Change	-52.32%	-0.56%	-59.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	City Area Code CityAreaCode	240
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Address Address Line1 EntityAddressAddressLine1	15245 Shady Grove Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 455
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Central Index Key EntityCentralIndexKey	0001228627
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4234141
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity File Number EntityFileNumber	001-34079
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	REXAHN PHARMACEUTICALS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-3516358
	dei	Local Phone Number LocalPhoneNumber	268-5300
	dei	Security12b Title Security12bTitle	Common Stock, $.0001 par value
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Trading Symbol TradingSymbol	REXN
	rexn	Contingent Value Rights Ip Term ContingentValueRightsIpTerm	P10Y
CY2020Q2	rexn	Contingent Value Rights Percentage ContingentValueRightsPercentage	0.90
CY2020Q2	rexn	Investment Warrants Fair Value InvestmentWarrantsFairValue	268811
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	127653
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	69069
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2511158
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	46385
	rexn	Investment Warrants Exercised Weighted Average Exercise Price InvestmentWarrantsExercisedWeightedAverageExercisePrice
CY2019Q4	rexn	Investment Warrants Fair Value InvestmentWarrantsFairValue	41717
	rexn	Investment Warrants Fair Value Assumptions Equivalent Risk Free Rate InvestmentWarrantsFairValueAssumptionsEquivalentRiskFreeRate	0.0016
CY2019	rexn	Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent	0.50
CY2020Q2	rexn	Average Of Five Lowest Volume Weighted Average Trading Prices AverageOfFiveLowestVolumeWeightedAverageTradingPrices	0.85
CY2020Q2	rexn	Cash At Closing CashAtClosing	0
CY2020Q2	rexn	Cash Requirement CashRequirement	0
CY2020Q2	rexn	Contingent Value Rights Ip Percentage ContingentValueRightsIpPercentage	0.75
	rexn	Contingent Value Rights License Term ContingentValueRightsLicenseTerm	P15Y
CY2019Q4	rexn	Deferred Tax Assets Book Tax Differences On Assets And Liabilities DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities	464000
CY2020Q2	rexn	Deferred Tax Assets Book Tax Differences On Assets And Liabilities DeferredTaxAssetsBookTaxDifferencesOnAssetsAndLiabilities	227000
	rexn	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00
	rexn	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	1
	rexn	Defined Contribution Plan Maximum Annual Contribution Per Employee Additional Percent On Deferral DefinedContributionPlanMaximumAnnualContributionPerEmployeeAdditionalPercentOnDeferral	0.5
CY2020Q2	rexn	Exchange Ratio Formula ExchangeRatioFormula	100000
	rexn	Investment Warrants Exercised Number InvestmentWarrantsExercisedNumber
	rexn	Investment Warrants Fair Value Assumptions Estimated Additional Shares Issued Upon Dilutive Event InvestmentWarrantsFairValueAssumptionsEstimatedAdditionalSharesIssuedUponDilutiveEvent	0.90
CY2019	rexn	Investment Warrants Fair Value Assumptions Estimated Dividend InvestmentWarrantsFairValueAssumptionsEstimatedDividend
	rexn	Investment Warrants Fair Value Assumptions Estimated Dividend InvestmentWarrantsFairValueAssumptionsEstimatedDividend
CY2019	rexn	Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate	1.02
	rexn	Investment Warrants Fair Value Assumptions Estimated Future Volatility Rate InvestmentWarrantsFairValueAssumptionsEstimatedFutureVolatilityRate	1.34
CY2019	rexn	Investment Warrants Fair Value Assumptions Trading Market Prices InvestmentWarrantsFairValueAssumptionsTradingMarketPrices	1.91
	rexn	Investment Warrants Fair Value Assumptions Trading Market Prices InvestmentWarrantsFairValueAssumptionsTradingMarketPrices	2.84
	rexn	Investment Warrants Issued Number InvestmentWarrantsIssuedNumber
	rexn	Investment Warrants Issued Weighted Average Exercise Price InvestmentWarrantsIssuedWeightedAverageExercisePrice
	rexn	Investment Warrants Weighted Average Remaining Contractual Term InvestmentWarrantsWeightedAverageRemainingContractualTerm	P3Y2M12D
CY2018Q1	rexn	Licensing Revenue Agreement Percent LicensingRevenueAgreementPercent	0.5
CY2020Q2	rexn	Pre Merger Financing PreMergerFinancing	21150000
CY2020Q2	rexn	Pre Merger Financing Ownership Of Combined Company PreMergerFinancingOwnershipOfCombinedCompany	0.15
CY2020Q2	rexn	Pre Merger Valuation PreMergerValuation	120000000
CY2009Q2	rexn	Research And Developement Agreement One Time Milestone Payment ResearchAndDevelopementAgreementOneTimeMilestonePayment	1000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q2	rexn	Termination Fee TerminationFee	750000
CY2019	rexn	Warrant Fundamental Transaction Timing Date WarrantFundamentalTransactionTimingDate	2020-04
	rexn	Warrant Fundamental Transaction Timing Date WarrantFundamentalTransactionTimingDate	2020-09
CY2020Q2	rexn	Warrant Liabilities WarrantLiabilities	268811
CY2019Q4	rexn	Warrants Exercise Price WarrantsExercisePrice	22.10
	rexn	Warrants Issued WarrantsIssued	4735913
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1265731
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2190753
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	56019
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4864
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	271723
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	290181
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2084
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	173278144
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	173423515
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	288653
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	127653
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	145371
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69069
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	288653
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	145371
CY2019Q4	us-gaap	Assets Assets	12968772
CY2020Q2	us-gaap	Assets Assets	10249074
CY2019Q4	us-gaap	Assets Current AssetsCurrent	12663973
CY2020Q2	us-gaap	Assets Current AssetsCurrent	10026604
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2997220
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2997220
CY2020Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2084
CY2019Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2995136
CY2019Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	2997220
CY2020Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	9200000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8744301
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7310049
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9219547
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9208951
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1434252
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10596
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1921489
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4019141
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4019141
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4019141
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4019141
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	402
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	402
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1500000
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	650000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2020Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43844000
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44843000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1191000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	540000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45499000
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45610000
CY2019Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	18506
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	21014
CY2020Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9785
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.02
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	22077
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18458
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
	us-gaap	Lease Cost LeaseCost	150079
CY2019Q2	us-gaap	Lease Cost LeaseCost	53788
	us-gaap	Lease Cost LeaseCost	85344
CY2020Q2	us-gaap	Lease Cost LeaseCost	42880
	us-gaap	Investment Income Interest InvestmentIncomeInterest	40461
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6042
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1940854
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-427483
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	227094
CY2020Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	168702
CY2020Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9594
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3035538
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1340016
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3372898
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2116891
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4807280
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2464284
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3097928
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2511158
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1231816
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	925022
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1500000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-850000
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-6706
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	3302
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22308
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	370447
	us-gaap	Investment Income Interest InvestmentIncomeInterest	178035
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	96650
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3000000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6186631
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3010596
	us-gaap	Net Income Loss NetIncomeLoss	-4807280
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2464284
	us-gaap	Net Income Loss NetIncomeLoss	-3097928
CY2020Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.11
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	143801
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	65364
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	78437
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7604
CY2019Q4	us-gaap	Liabilities Liabilities	3010818
CY2020Q2	us-gaap	Liabilities Liabilities	3245761
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12968772
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10249074
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2976950
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	41717
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	268811
	us-gaap	Nature Of Operations NatureOfOperations	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;text-indent:-21.6pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-weight:bold;font-family:Times New Roman;font-size: 11pt"> <a name="_Hlk512345999"></a><font style="display: inline;">1.</font><font style="display: inline;;font-size: 11pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;">Operations and Organization</font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Operations</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations have been the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat.  The Company had an accumulated deficit of </font><font style="display: inline;">$166,420,604</font><font style="display: inline;"> at June 30, 2020 and anticipates incurring losses in the foreseeable future.  </font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">On June 17, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Original Merger Agreement,” and as amended on June 29, 2020, the “Merger Agreement”) with Razor Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Ocuphire Pharma Inc., a Delaware corporation (“Ocuphire”), pursuant to which, among other things, and subject to the satisfaction and waiver of certain conditions set forth in the Merger Agreement, Merger Sub will merge with and into Ocuphire, with Ocuphire continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the “Merger”).  See Note 2, </font><font style="display: inline;font-style:italic;">Merger Agreement and Pre-Merger Financing, </font><font style="display: inline;">for further information.</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The Company believes that its cash and cash equivalents of approximately </font><font style="display: inline;">$9.2</font><font style="display: inline;"> million as of June 30, 2020 will be sufficient to cover its cash flow </font><font style="display: inline;">requirements for its current activities</font><font style="display: inline;"> </font><font style="display: inline;">for</font><font style="display: inline;"> at least the next 12 months from the date these financial statements were issued</font><font style="display: inline;">, assuming the Merger does not close</font><font style="display: inline;">.</font><font style="display: inline;">    </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Basis of Presentation</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements.  In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of June 30, 2020 and December 31, 2019 and of the results of operations, comprehensive loss, and stockholders’ equity for the three and six months ended June 30, 2020 and 2019 and the cash flows for the six months ended June 30, 2020 and 2019 have been included.  Operating results for the three and six months ended June 30, 2020 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2020. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”).  Information included in the condensed balance sheet as of December 31, 2019 has been derived from the Company’s audited financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K.  The unaudited condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;"></font> </p> <p style="margin:0pt;text-indent:23.75pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <a name="_Hlk512346000"></a><font style="display: inline;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future.  Actual results may ultimately differ from these estimates.  These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;color:#000000;">COVID-19 Pandemic</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;color:#000000;">The outbreak of the COVID-19 disease, which the World Health Organization declared a pandemic in March 2020, has led to disruption in the global economy and the biopharmaceutical industry. The extent of the COVID-19 pandemic’s impact on the Company’s business, financial condition and results of operations, as well as the Company’s ability to consummate the Merger, is highly uncertain and will depend on various factors, including the duration and scope of the pandemic, restrictions on business and social distancing guidelines that may be requested or mandated by governmental authorities, other actions taken to contain the impact of the pandemic, and the Company’s access to additional capital.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:10.8pt 0pt 0pt 23.75pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 1pt"> <font style="display: inline;font-weight:bold;font-size:1pt;background-color:yellow;"></font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7653828
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2901449
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2511158
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2118889
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	524133
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-186633
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-162660
	us-gaap	Operating Expenses OperatingExpenses	6926169
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	2988417
	us-gaap	Operating Expenses OperatingExpenses	4061295
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	2348498
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6926169
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2988417
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2911295
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2348498
	us-gaap	Operating Lease Cost OperatingLeaseCost	127407
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	47129
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	6659
	us-gaap	Operating Lease Cost OperatingLeaseCost	73541
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	36770
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	136197
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139765
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	136197
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	63605
	us-gaap	Operating Lease Payments OperatingLeasePayments	120700
	us-gaap	Operating Lease Payments OperatingLeasePayments	76843
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	203348
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139477
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	156586000
CY2020Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	160154000
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	25015
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19781
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2084
	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	19383
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	8887566
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	447206
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	817653
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7653828
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6000000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3000000
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	5500
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	347493
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	347493
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75770
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57312
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3890631
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1648401
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	688397
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	231607
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163322676
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-166420604
	us-gaap	Revenues Revenues
CY2019Q2	us-gaap	Revenues Revenues
	us-gaap	Revenues Revenues	1150000
CY2020Q2	us-gaap	Revenues Revenues
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	380935
CY2019Q4	us-gaap	Security Deposit SecurityDeposit	25681
CY2020Q2	us-gaap	Security Deposit SecurityDeposit	25681
	us-gaap	Share Based Compensation ShareBasedCompensation	288653
	us-gaap	Share Based Compensation ShareBasedCompensation	145371
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10562890
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	15939956
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	13623106
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	9957954
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	9445402
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	7003313
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7553828
	us-gaap	Use Of Estimates UseOfEstimates	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-indent:23.75pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt 0pt 0pt 23.75pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman;font-size: 11pt"> <font style="display: inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future.  Actual results may ultimately differ from these estimates.  These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.</font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Variable Lease Cost VariableLeaseCost	22672
	us-gaap	Variable Lease Cost VariableLeaseCost	11803
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	6110
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3900208
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4019141

Files In Submission

Name	View Source	Status
0001140361-20-018406-index-headers.html	Edgar Link	pending
0001140361-20-018406-index.html	Edgar Link	pending
0001140361-20-018406.txt	Edgar Link	pending
0001140361-20-018406-xbrl.zip	Edgar Link	pending
brhc10014414_10q.htm	Edgar Link	pending
brhc10014414_ex2-1.htm	Edgar Link	pending
brhc10014414_ex31-1.htm	Edgar Link	pending
brhc10014414_ex32-1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rexn-20200630.xml	Edgar Link	completed
rexn-20200630.xsd	Edgar Link	pending
rexn-20200630_cal.xml	Edgar Link	unprocessable
rexn-20200630_def.xml	Edgar Link	unprocessable
rexn-20200630_lab.xml	Edgar Link	unprocessable
rexn-20200630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRD
Opus Genetics, Inc. Stock $ird

2020 Q3 Form 10-Q Financial Statement

#000114036120018406 Filed on August 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRD Opus Genetics, Inc. Stock $ird

2020 Q3 Form 10-Q Financial Statement

#000114036120018406 Filed on August 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRD
Opus Genetics, Inc. Stock $ird